Sharda Cropchem Ltd

- There is no mention of any current or planned fundraising through debt or equity in the transcript. - The company remains net debt-free as of March 31, 2025. - Cash, bank balances, and liquid investments stand at INR 558 crores. - Capital expenditure (capex) for FY '25 was INR 420 crores, with guidance to maintain capex in the range of INR 400-450 crores in FY '26 for ongoing product registrations. - No indication of raising funds through debt or equity was provided during the call or Q&A.

- For FY '25, Sharda Cropchem's capex was INR 420 crores. - The company is confident in ongoing product registrations. - Capex guidance for FY '26 is planned to be in the range of INR 400 crores to INR 450 crores. - The capex is aimed at supporting product registrations and business growth. - Strategic investments focus on expanding registrations and market share globally.

- Sharda Cropchem is targeting overall top-line growth of 10% to 15% in FY '26. - Volume growth expectation is stronger, with 10% to 15% growth forecasted for both agrochemical and non-agrochemical segments. - Globally, the company’s current 4%-5% global market share offers scope to increase, meaning a 1% global share gain equates to 20%-25% volume growth for them. - Regional volume growth in FY '25 was significant: Europe (58%), NAFTA (36%), LatAm (25%). - Prices, expected to have pressured margins in FY '25, are forecasted to improve by 10%-15% in FY '26, potentially driving margin expansion. - The company is confident despite external pressures like U.S. tariffs due to limited sourcing alternatives globally. - Capex for ongoing product registrations is expected to be INR400-450 crores in FY '26, supporting growth.

- FY '26 Revenue Growth: Targeting 10%-15% top-line growth, driven mainly by volume increases and expected pricing improvement. - Volume Growth: Expected 10%-15% growth in both agrochemical and non-agrochemical segments. - Margin Expansion: Anticipated EBITDA margin of 15%-18% for FY '26, primarily led by gross margin expansion due to price recovery and improved product mix. - Pricing Outlook: Gradual price increases beginning Q1 FY '26 expected, with potential 10%-15% improvement in prices as market normalizes from 2024 oversupply. - Profitability: EBITDA and PAT expected to sustain growth trends, with overall positive earnings momentum. - Market Share: Focus on increasing global market share from current ~4%-5%, providing scope for higher volume and earnings growth. - Operating Efficiencies: Improved working capital cycle and tight inventory management support profitability. - No inventory write-offs expected, supporting stable cost management and earnings quality.

The transcript provided from the Sharda Cropchem Limited Q4 FY '25 earnings call does not explicitly mention details about their current or expected order book or pending orders. However, key insights related to business growth and demand include: - Significant volume growth in Q4 FY '25: over 50% year-on-year overall; agrochemical segment volume growth at 48%. - Strong demand in Europe, Latin America, and NAFTA regions. - The company maintains close customer relationships to align production with demand, especially in Europe. - Discussions highlight confidence in achieving 10% to 15% revenue growth guidance for FY '26. - No explicit numbers or status on order book or pending orders were disclosed during the call. If you require more detailed order book information, the company suggests contacting their Investor Relations team.